Find a Physician | How to Contribute | About Us | Clinical Trials
 
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Lung

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug).

Status: Accepting New Patients
Principal Investigator: Nisha Mohindra

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

The purpose of this study is to test any good and bad effects of the combination of study drugs called ipilimumab and nivolumab in treating rare cancers and cancers of unknown primary origin.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888_ Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to find out what effects (good and/or bad) Veliparib has, when added to standard combination therapy of Radiation, Carboplatin, and Paclitaxel, on participants and their non-small cell lung cancer.

Status: Accepting New Patients
Principal Investigator: Victoria Villaflor

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin In Stage IIIb/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

The purpose of this study is to assess the safety of nivolumab in combination with Abraxane (nab-paclitaxel) based chemotherapy treatments.

Status: Accepting New Patients
Principal Investigator: Aparna Kalyan

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

The purpose of this study is to evaluate and compare the effects (good and/or bad) of different targeted study drugs to the standard chemotherapy.

Status: Accepting New Patients
Principal Investigator: Young Chae

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance For Small Cell Lung Cancer

The purpose of the first portion of this study is to test whether whole brain radiation that minimizes dose to the hippocampus (a brain structure that is important for memory) during whole-brain radiation is effective as the usual treatment, whole-brain radiation, in decreasing the chance of cancer spreading to the brain. The second portion of this study will test if hippocampal avoidance decreases the side effects of radiation on memory and other thought processes.

Status: Accepting New Patients
Principal Investigator: Timothy Kruser

A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer

The main goals of the research study are to determine the highest safe dose of veliparib in combination (given together) with carboplatin and etoposide, to understand how the body absorbs and handles veliparib when given together with carboplatin and etoposide, and to evaluate the safety and tolerability of veliparib when taken without the chemotherapy combination.

Status: Accepting New Patients
Principal Investigator: Young Chae

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

To determine the efficacy of MGCD265 in the selected patient population.

Status: Accepting New Patients
Principal Investigator: Nisha Mohindra

Phase I/II Study Of Carboplatin/Nab-Paclitaxel and MK-3475 for Advanced Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to test the safety of the study drug called MK-3475 in combination with routine care nab-paclitaxel and carboplatin chemotherapy.

Status: Accepting New Patients
Principal Investigator: Nisha Mohindra

SHERLOC: A Phase 2 Study of MM-121 in Combination with Docetaxel versus Docetaxel Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The main purpose of this study is to find out more about the side effects of MM-121 when combined with docetaxel or pemetrexed, and to learn if cancer cell growth (disease progression) is delayed in people taking MM-121 with docetaxel or pemetrexed.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

last updated: Wed - August 16, 2017 - 04:05 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.